Protective effects of certoparin sodium, a low molecular weight heparin derivative, in experimental atherosclerosis

2004 ◽  
Vol 339 (1-2) ◽  
pp. 105-115 ◽  
Author(s):  
Perinkulam Ravi Deepa ◽  
Palaninathan Varalakshmi
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Experimental Atherosclerosis ◽  
Low Molecular Weight ◽  
Protective Effects ◽  
Heparin Derivative

Heparin-Associated Thrombocytopenia Treatment with Low Molecular Weight Heparin

1986 ◽  
Vol 55 (01) ◽  
pp. 037-039 ◽  
Author(s):  
Jean-F Vitoux ◽  
Jean-F Mathieu ◽  
Martine Roncato ◽  
Jean-N Fiessinger ◽  
Martine Aiach
Keyword(s):  
Molecular Weight ◽  
Clinical Improvement ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
Antithrombotic Activity ◽  
Heparin Derivative

SummaryEight patients with heparin associated thrombocytopenia (HAT) were treated by a low molecular weight heparin derivative (LMW). Biological and clinical improvement occurred in all patients. This efficiency confirms the antithrombotic activity of LMW and allows its use in patients with HAT.

scholarly journals Anti-inflammatory effects of low molecular weight heparin derivative in a rat model of carrageenan-induced pleurisy

2009 ◽  
Vol 13 (8b) ◽  
pp. 2704-2712 ◽  
Author(s):  
Matteo Ceccarelli ◽  
Daniele Bani ◽  
Lorenzo Cinci ◽  
Silvia Nistri ◽  
Caterina Uliva ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Rat Model ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
Anti Inflammatory ◽  
Heparin Derivative

Long-term Treatment of Acute Deep Venous Thrombosis With Low-Molecular-Weight Heparin Derivative

JAMA ◽  
1988 ◽  
Vol 259 (8) ◽  
pp. 1180-1181 ◽  
Author(s):  
J.-F. Vitoux ◽  
J.-N. Fiessinger ◽  
M. Roncato ◽  
J.-M. Pernes ◽  
P. Brenot ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Venous Thrombosis ◽  
Deep Venous Thrombosis ◽  
Low Molecular Weight Heparin ◽  
Term Treatment ◽  
Low Molecular Weight ◽  
Long Term Treatment ◽  
Heparin Derivative

A new low molecular weight heparin derivative. In vitro and in vivo studies

1983 ◽  
Vol 31 (4) ◽  
pp. 611-621 ◽  
Author(s):  
Martine Aiach ◽  
Anne Michaud ◽  
Jean-Luc Balian ◽  
M. Lefebvre ◽  
M. Woler ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
In Vivo Studies ◽  
Low Molecular Weight ◽  
Heparin Derivative

Pharmacological Properties of a Low Molecular Weight Butyryl Heparin Derivative (C4-CY 216) with Long Lasting Effects

1992 ◽  
Vol 67 (03) ◽  
pp. 346-351 ◽  
Author(s):  
S Saivin ◽  
M Petitou ◽  
J C Lormeau ◽  
D Dupouy ◽  
P Sié ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Specific Activity ◽  
Parent Compound ◽  
Factor Xa ◽  
Low Molecular Weight ◽  
Pharmacological Properties ◽  
Factor Xa Inhibition ◽  
Antifactor Xa ◽  
Heparin Derivative

SummaryWe have investigated the pharmacological properties of an O-acylated butyryl derivative of the low molecular weight heparin CY 216 (C4-CY 216). In a purified system the ability of C4-CY 216 to catalyze thrombin and factor Xa inhibition was comparable to that of CY 216. The antithrombin and antifactor Xa catalytic efficiencies of C4-CY 216 were reduced 217 and 12 times respectively when albumin (10 mg ml-1) was added to the reagents, while those of CY 216 were essentially unchanged. In plasma, the antifactor Xa specific activity of C4-CY 216 was close to that of CY 216 but the antithrombin specific activity was 2 times lower. After bolus and continuous intravenous injection to rabbits, the clearances of the two activities of C4-CY 216 were on average half the corresponding values of CY 216. After subcutaneous injection, the bioavailability of C4-CY 216 was comparable to that of CY 216. C4-CY 216 was as potent as CY 216 in preventing venous thrombosis in the thromboplastin-Wessler model and the duration of the antithrombotic effect was longer than that of the parent compound. The chemical alteration of CY 216 did not enhance the prohaemorrhagic effect in the rat tail transection model. Therefore, the new concept of heparin derivative having a low clearance and long lasting effects that we have recently reported for unfractionated heparin may also be applied to a low molecular weight heparin.

Sign in / Sign up

Export Citation Format

Share Document